Advent International, a United States-based global private equity company, has entered into discussions to acquire Zentiva, Sanofi's European generics business, it is reported today.
The deal is valued at EUR1.9bn and it is likely to be completed by the end of 2018, subject to execution of definitive agreements, followed by approvals from relevant regulatory authorities among other conditions.
Sanofi is looking to sell Zentiva after considering the European generics business to be non-core. The deal is also part of the French drugmaker's strategy to simplify and reshape its overall business. Czech Republic-based Zentiva has a generics portfolio that includes several therapeutic areas like cardiovascular, central nervous system, anti-infectives, anti-inflammatory and pain, and respiratory.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling